These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100 [TBL] [Abstract][Full Text] [Related]
9. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060 [TBL] [Abstract][Full Text] [Related]
11. Comparison of platelet aggregation response in switching regimen from prasugrel to clopidogrel between CYP2C19 extensive versus non-extensive metabolizers. Ebisawa S; Ueki Y; Mochidome T; Senda K; Nishimura H; Saigusa T; Miura T; Motoki H; Koyama J; Ikeda U Cardiovasc Interv Ther; 2018 Jul; 33(3):277-284. PubMed ID: 28681220 [TBL] [Abstract][Full Text] [Related]
12. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. Giustino G; Redfors B; Kirtane AJ; Mehran R; Dangas GD; Witzenbichler B; Neumann FJ; Weisz G; Généreux P; Maehara A; McAndrew T; Farhan S; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Gurbel P; Ben-Yehuda O; Stone GW JACC Cardiovasc Interv; 2018 Jul; 11(13):1277-1286. PubMed ID: 29908967 [TBL] [Abstract][Full Text] [Related]
13. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
14. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524 [TBL] [Abstract][Full Text] [Related]
16. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114 [TBL] [Abstract][Full Text] [Related]
17. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. Ohno Y; Kitahara H; Fujii K; Kohno Y; Ariyoshi N; Nishi T; Fujimoto Y; Kobayashi Y J Cardiol; 2019 Jan; 73(1):51-57. PubMed ID: 30055865 [TBL] [Abstract][Full Text] [Related]
18. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215 [TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Sustainability of Using Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis. Galli M; Occhipinti G; Benenati S; Laborante R; Ortega-Paz L; Franchi F; D'Amario D; Nerla R; Castriota F; Frati G; Biondi-Zoccai G; Sciarretta S; Angiolillo DJ Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):526-536. PubMed ID: 38754988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]